MD Anderson Delivers a Triple Punch to Pancreatic Cancer

A recent study by researchers at the University of Texas MD Anderson Cancer Center found that targeting checkpoints in both T cells and myeloid suppressor cells led to a curative response in pancreatic cancer models.

While pancreatic ductal adenocarcinoma (PDAC) is typically considered non-immunogenic, the team, led by Ronald DePinho, M.D., professor of cancer biology and past president of MD Anderson, may have discovered an immunotherapeutic path forward in a cancer with a dire prognosis.